This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Monno, S. Articles by Lowe, W. L. Search for Related Content PubMed PubMed Citation Articles by Monno, S. Articles by Lowe, W. L., Jr.

Insulin-Like Growth Factor I Activates c-Jun N-Terminal Kinase in MCF-7 Breast Cancer Cells¹

Center for Endocrinology, Metabolism, and Molecular Medicine, Department of Medicine, Veterans Administration Chicago Healthcare System-Lakeside Division and Northwestern University Medical School, Chicago, Illinois 60611

Address all correspondence and requests for reprints to: William L. Lowe, Jr., M.D., Center for Endocrinology, Metabolism, and Molecular Medicine, Tarry 15–703, Northwestern University Medical School, 303 East Chicago Avenue, Chicago, Illinois 60611. E-mail: wlowe{at}nwu.edu

Insulin-like growth factor I (IGF-I) is an important mediator of breast cancer cell growth, although the signaling pathways important for IGF-I-mediated effects in breast cancer cells are still being elucidated. We had demonstrated previously that increased intracellular cAMP in MCF-7 breast cancer cells inhibited cell growth and IGF-I-induced gene expression, as determined using a reporter gene assay. This effect of cAMP on IGF-I signaling was independent of IGF-I-induced activation of the mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 (ERK1 and -2). To determine whether this effect of cAMP may be mediated via another mitogen-activated protein kinase, the ability of IGF-I to activate the c-Jun N-terminal kinases (JNKs) was investigated. Treatment of MCF-7 cells with 100 ng/ml IGF-I increased the level of phosphorylated JNK, as determined by Western blot analysis. JNK phosphorylation was not evident until 15 min after treatment with IGF-I, and peak levels of phosphorylation were present at 30–60 min. This was in contrast to ERK phosphorylation, which was present within 7.5 min of IGF-I treatment. Determination of JNK activity using an immune complex assay demonstrated a 3.3- and 3.5-fold increase in JNK1 and -2 activity, respectively, 30 min after treatment with 100 ng/ml IGF-I. The use of PD98059, which inhibits activation of ERK1 and -2, and LY 294002, an inhibitor of phosphatidylinositol 3-kinase, demonstrated that IGF-I-induced activation of JNK1 is independent of ERK and phosphatidylinositol 3-kinase activation. In contrast, increasing intracellular cAMP with forskolin resulted in abrogation of IGF-I-induced JNK activity. In summary, these data demonstrate that IGF-I activates the JNKs in MCF-7 breast cancer cells and, taken together with the results of our previous study, suggest that JNK may contribute to IGF-I-mediated gene expression and, possibly, cell growth in MCF-7 breast cancer cells.

This article has been cited by other articles:

				Y. C. Henderson, M. J. Fredrick, and G. L. Clayman Differential Responses of Human Papillary Thyroid Cancer Cell Lines Carrying the RET/PTC1 Rearrangement or a BRAF Mutation to MEK1/2 Inhibitors Arch Otolaryngol Head Neck Surg, August 1, 2007; 133(8): 810 - 815. [Abstract] [Full Text] [PDF]

				A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights Endocr. Rev., February 1, 2007; 28(1): 20 - 47. [Abstract] [Full Text] [PDF]

				Y. Lin, Q. Yang, X. Wang, and Z.-g. Liu The Essential Role of the Death Domain Kinase Receptor-interacting Protein in Insulin Growth Factor-I-induced c-Jun N-terminal Kinase Activation J. Biol. Chem., August 18, 2006; 281(33): 23525 - 23532. [Abstract] [Full Text] [PDF]

				Y. H. Ibrahim and D. Yee Insulin-Like Growth Factor-I and Breast Cancer Therapy Clin. Cancer Res., January 15, 2005; 11(2): 944s - 950s. [Abstract] [Full Text] [PDF]

				P. Fischer-Posovszky, H. Tornqvist, K.-M. Debatin, and M. Wabitsch Inhibition of Death-Receptor Mediated Apoptosis in Human Adipocytes by the Insulin-Like Growth Factor I (IGF-I)/IGF-I Receptor Autocrine Circuit Endocrinology, April 1, 2004; 145(4): 1849 - 1859. [Abstract] [Full Text] [PDF]

				G. Liu, W.-Y. Ma, A. M. Bode, Y. Zhang, and Z. Dong NS-398 and Piroxicam Suppress UVB-induced Activator Protein 1 Activity by Mechanisms Independent of Cyclooxygenase-2 J. Biol. Chem., January 17, 2003; 278(4): 2124 - 2130. [Abstract] [Full Text] [PDF]

				G. Liu, A. Bode, W.-Y. Ma, S. Sang, C.-T. Ho, and Z. Dong Two Novel Glycosides from the Fruits of Morinda Citrifolia (Noni) Inhibit AP-1 Transactivation and Cell Transformation in the Mouse Epidermal JB6 Cell Line Cancer Res., August 1, 2001; 61(15): 5749 - 5756. [Abstract] [Full Text] [PDF]

				W. Liu, Y. Liu, and W. L. Lowe Jr. The Role of Phosphatidylinositol 3-Kinase and the Mitogen-Activated Protein Kinases in Insulin-Like Growth Factor-I-Mediated Effects in Vascular Endothelial Cells Endocrinology, May 1, 2001; 142(5): 1710 - 1719. [Abstract] [Full Text]

				A. Gagnon, P. Dods, N. Roustan-Delatour, C.-S. Chen, and A. Sorisky Phosphatidylinositol-3,4,5-Trisphosphate Is Required for Insulin-Like Growth Factor 1-Mediated Survival of 3T3-L1 Preadipocytes Endocrinology, January 1, 2001; 142(1): 205 - 212. [Abstract] [Full Text] [PDF]

				D. Krause, A. Lyons, C. Fennelly, and R. O'Connor Transient Activation of Jun N-terminal Kinases and Protection from Apoptosis by the Insulin-like Growth Factor I Receptor Can Be Suppressed by Dicumarol J. Biol. Chem., May 25, 2001; 276(22): 19244 - 19252. [Abstract] [Full Text] [PDF]